Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).

PET CT

Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years.

Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive bladder cancer (MIBC).

Guidelines do not recommend FDG-Positron Emission Tomography (PET) Computed Tomography (CT), but rather CT for lymph node and metastatic staging, despite its low accuracy. We performed a retrospective analysis of patients undergoing PET CT for localized MIBC in two centers, to help define the utility of PET CT in this setting.

Background:

Bladder cancer is the second most frequent genito-urinary cancer, and the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Curative treatment of muscle invasive urothelial carcinoma localized to the bladder includes cisplatin-based neoadjuvant chemotherapy, followed by radical cystectomy with lymph nodes dissection. Nonetheless, surgery indications depend on pre-operative staging regarding nodes and metastatic involvement.

Computed Tomography (CT) scan is the reference imaging study for loco-regional and metastatic staging. Lymph node involvement evaluation is based on morphologic criteria only. Its sensitivity lies between 30 and 53% and its specificity between 67 and 91%. Yet, optimal node staging is crucial for therapeutic decision.

FDG-Positron Emission Tomography (PET) CT, using both morphologic and functional criteria, could help for node staging in muscle invasive bladder cancer assessment, especially by detecting infracentimetric involved lymph nodes. Moreover, it could be useful for detecting distant metastasis.

Objective:

To evaluate the accuracy of the PET CT for lymph node staging and to determine the rate of treatment modification according to PET CT results

Methods:

Retrospective study based on the medical records of every patient undergoing a PET CT at the time of diagnosis of MIBC from 01/2005 to 12/2017 in Bordeaux (Bergonie Institute and University Hospital). PET CT could have been done before any treatment (PET 1) and/or after neo-adjuvant chemotherapy and before surgery (PET 2).

Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer

Description: Assess differences between planned management before knowing the FDG-PET CT results and treatment actually received.

Comparison of lymph nodes staging on PET CT (according to EORTC criteria) and lymph nodes staging on pathological report, according to the AJCC TNM Staging System for Bladder Cancer 8th ed., 2017.

Evaluation of the concordance rate between PET CT results (according to EORTC criteria) and CT scan results (according to RECIST 1.1) for lymph node and metastatic staging according to the AJCC TNM Staging System for Bladder Cancer 8th ed., 2017.

Comparison of PET-CT TNM staging between patients with and patients without a Pathological Complete Response

Comparison of Recurrence Free Survival for patients with and patients without a Complete Metabolic Response (according to EORTC criteria)

Institut Bergonié

Mouth and Tooth Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Mouth Neoplasms

Squamous Cell Carcinoma of Head and Neck

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Head and Neck Neoplasms

Mouth Diseases

Stomatognathic Diseases

Oral Squamous Cell Carcinoma

Oral Cancer

Lip and Oral Cavity Cancer

paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists

Biopsy Specimens Histopathology

Manahal Rahat, BDS

Maj. Umair Aslam Shahzad, MBBS, FCPS, Dip RCPath UK

Manahil Rahat, BDS

Cancer of the oral mucosa, also known as oral squamous cell carcinoma (OSCC), occurs as an ulceroproliferative lesion that can develop at any site in the mouth, from the lips to oropharynx. OSCC (Oral squamous cell carcinoma) is a biologically aggressive tumor and this has piqued interest in research into several prognostic histopathological indicators during the past few decades. The AJCC 8th edition TNM staging system incorporates histopathological factors including depth of invasion (DOI) that affect patient outcomes. Numerous studies have linked a poor prognosis and increased locoregional failure with certain \&quot;patterns of invasion\&quot; (POI) in OSCC. However, this factor is not utilized for treatment decision making and for outcome assessment.

The management and prognosis of oral squamous cell carcinoma (OSCC) depends on tumor stage, differentiation, perineural and lymphovascular invasion, depth of invasion, margin status, lymph node (LN) metastasis and extranodal extension. We will evaluate the relationship of these histopathological parameters with cohesive and non cohesive worst patterns of invasion (WPOI) in OSCC. The purpose of this cross-sectional study is to determine that presence of non-cohesive WPOI is associated with advanced T stage, poor differentiation, PNI, greater depth of invasion, and higher chances of nodal metastasis. WPOI is associated with poor DFS (disease free survival), treatment intensification in early stage disease with non-cohesive WPOI may improve survival.

Therefore, it should also be included in routine reporting protocol for OSCC to aid in describing the aggressive behaviour of disease.

Oral cancer is one of the most often diagnosed types of the disease in Pakistan (Globocan, 2020 Pakistan). Squamous cell carcinomas account for over 90% of oral cancers (Anwar et al., 2020) . Several indicators point to a poor prognosis for OSCC, such as advanced tumor stage, higher tumor grade, extra capsular extension, nodal metastases, greater depth of invasion, lymphovascular invasion, poor differentiation, positive surgical margins, and perineural invasion have all been shown to be related with poor prognosis of patients with OSCC (Khan et al., 2023) . These factors have been rarely evaluated in Pakistani population.

Although there have been significant advances in the management of other types of cancer, OSCC still has few therapeutic options. The overall five-year survival rate for this illness remains about 50% despite substantial study over the preceding few decades.

(Chen et al., 2018) . Surgery followed by adjuvant radiation therapy and/or chemotherapy is still considered the gold standard for treating cancer. Early stage oral tongue carcinomas that are 4 mm or deeper at diagnosis, or that have a development pattern of small cell islands or satellites, should be treated as high-risk tumors requiring a multimodal approach (Lakhera et al., 2023) . Previous research into the significance of tumor budding in oral cavity malignancies has linked it to increased rates of lymph node metastases, relapse, and poor overall survival.

(Almangush et al., 2018) .Similar is seen with tumours that have greater depth of invasion. (Moeckelmann N, 2018)

The invasive tumor front is the transition zone between the tumors and the surrounding stroma. The infiltration pattern of tumors at the tumor front has been studied in a few prior investigations. (Chatterjee et al., 2019) This needs separate attention now as The College of American Pathologists now includes the reporting of oral cavity cancers based on the patterns of tumor invasion but they are not well-established prognostic variables.

(Seethala et al., 2021) This is due to the dearth of published research on the topic of invasive tumors. (Arora et al., 2017) . Despite its low prognostic value, the World Health

7

Organization\&#39;s (WHO) 4th edition (2017) classification of OSCC still endorses a simple, differentiation-based histopathologic grading system that disregards important variables like tumour growth pattern and dissociation, stromal reactions (desmoplasia, local immune response), and tumor-stroma ratio. (Almangush et al., 2020) Several histological markers, easily evaluated on regular hematoxylin and eosin-stained sections, predict the outcome of OSCC. The aforementioned metrics are excellent predictors of future outcomes. These, along with WPOI, are simple and reliable prognostic indicators in early-stage OSCC that are linked to a worse prognosis. Since WPOI may aid in the individualised management of OSCC patients, it is recommended that it be evaluated in both resection and preoperative biopsy specimens as part of a standardised reporting format. (Chatterjee et al., 2019)

WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA

WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA: AN INDEPENDENT PROGNOSTIC INDICATOR

Correlation with cohesive (I-III) and non-cohesive (IV-V) worst patterns of invasive at tumor host interface in OSCC

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer	NCT04053101	Muscle Invasive...	PET CT	18 Years -	Institut Bergonié
WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA	NCT05927220	Oral Cancer Oral Cavity Can... Oral Squamous C...	Biopsy Specimen...	18 Years - 80 Years	Armed Forces Institute of Pathology Rawalpindi
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer	NCT04053101	Muscle Invasive...	PET CT	18 Years -	Institut Bergonié
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer	NCT04053101	Muscle Invasive...	PET CT	18 Years -	Institut Bergonié

Spots Global Cancer Trial Database for tnm staging

Every month we try and update this database with for tnm staging cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tnm staging

Every month we try and update this database with for tnm staging cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tnm staging cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.